Nivolumab CheckMate-274 Extended Results ASCO GU 2025 Continued Benefit in MIBC скачать в хорошем качестве

Nivolumab CheckMate-274 Extended Results ASCO GU 2025 Continued Benefit in MIBC

In this video, we delve into the latest findings from the extended 3-year follow-up of the CheckMate-274 trial, showcasing the ongoing benefits of adjuvant nivolumab in treating muscle-invasive bladder cancer (MIBC). Key Highlights: DFS and OS Benefits: Learn how nivolumab significantly extends disease-free survival and shows promising trends in overall survival, with a median OS not yet reached compared to 39.9 months in the placebo group. Study Details: We break down the study's design, including the patient cohorts where 353 received nivolumab and 356 received placebo in the intention-to-treat group, and 279 vs. 281 in the MIBC cohort. Impact Across NAC Status: Discover how these benefits hold true regardless of whether patients received neoadjuvant chemotherapy (NAC), with specific DFS and OS data for both groups. PD-L1 Expression Insights: Explore how PD-L1 status might influence patient outcomes, with notable OS rates in PD-L1-positive patients. Expert Commentary: Hear from leading oncologists Dr. Matthew I. Milowsky and Dr. Elizabeth R. Plimack as they discuss the implications of these results for clinical practice and future research directions. Safety Profile: Understand the treatment's safety, with no new signals of concern and a detailed look at common adverse events. Future Directions: Get a glimpse into upcoming research with the mention of the MODERN study, focusing on new biomarkers like circulating tumor DNA. Timestamps: 00:00:00 - Introduction to CheckMate-274 and Nivolumab in MIBC Welcome to the CheckMate-274 results on nivolumab in MIBC, presented by Dr. Matthew I. Milowsky at the 2025 ASCO GU Symposium. 00:00:10 - Dr. Milowsky's Quote on Trial Impact Dr. Milowsky from UNC School of Medicine highlights the 3-year follow-up benefits of nivolumab. 00:00:19 - Overview of CheckMate-274 Trial Discussion on the phase 3 trial design, comparing nivolumab to placebo in high-risk MIBC. 00:00:31 - Study Population and Design Details on the patient cohorts and follow-up periods. 00:00:46 - Disease-Free Survival (DFS) Results Presentation of the median DFS and hazard ratios for nivolumab and placebo groups. 00:01:00 - Interim Overall Survival (OS) Analysis Review of OS outcomes, including hazard ratios and long-term survival rates. 00:01:14 - PD-L1 Expression and OS Insights into how PD-L1 status correlates with survival outcomes. 00:01:26 - Safety Profile of Nivolumab Discussion on treatment-related adverse events and common side effects. 00:01:36 - Expert Commentary by Dr. Elizabeth R. Plimack Dr. Plimack's perspective on the study's implications and future treatment possibilities. 00:01:47 - Conclusion and Future Directions Summarization of the trial's confirmation of benefits and mention of upcoming research like the MODERN study. Subscribe for more updates on oncology research, treatment advancements, and expert discussions in cancer care. #Nivolumab #MIBC #CheckMate274 #Oncology #CancerResearch #BladderCancer #Immunotherapy #ASCO2025 Like, comment, and share if this video was informative for you or if you know someone who could benefit from this information! Disclaimer: This video provides educational content but does not replace professional medical advice. Always consult with a healthcare provider for medical decisions.